Liminatus Pharma, Inc. (LIMN)
| Market Cap | 8.08M -95.2% |
| Revenue (ttm) | n/a |
| Net Income | -10.21M |
| EPS | -0.43 |
| Shares Out | 44.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 704,724 |
| Open | 0.1800 |
| Previous Close | 0.1840 |
| Day's Range | 0.1770 - 0.1890 |
| 52-Week Range | 0.1592 - 33.6600 |
| Beta | 0.76 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 1, 2026 |
About LIMN
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Financial Performance
Financial StatementsNews
Liminatus Pharma to initiate Phase 1 clinical trial for IBA101 antibody
Liminatus plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement established immuno-...
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designe...
Liminatus Pharma prices 13.8M shares at 29c in public offering
Liminatus Pharma (LIMN) announced the pricing of its best-efforts public offering of 13,813,000 shares of its common stock and warrants to purchase up to 20,719,500 shares of common stock, at…
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-b...
Liminatus Pharma files to sell 6.9M shares of common stock, warrants
Maxim Group is exclusive placement agent for the offering.
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today ...
Liminatus Pharma Inc trading resumes
13:26 EDT Liminatus Pharma (LIMN) Inc trading resumes
Liminatus Pharma Inc trading halted, volatility trading pause
13:21 EDT Liminatus Pharma (LIMN) Inc trading halted, volatility trading pause
Liminatus Pharma to launch ‘American BNB Strategy’ subsidiary
Liminatus Pharma (LIMN) announced plans for a strategic expansion into the cryptocurrency and blockchain sector. The company intends to establish a dedicated subsidiary, named “American BNB Strategy,”...
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value Liminatus Id...
Liminatus Pharma evaluates formation of digital asset investment vehicle
Liminatus Pharma (LIMN) announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset investment v...
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed Strategic Internal Review initiated for treasur...
Liminatus Pharma entered into engagement agreement with Digital Offering
Liminatus Pharma (LIMN) announced it has entered into an engagement agreement with Digital Offering to serve as its exclusive placement agent in connection with the company’s evaluation of a potential...
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing paths Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backe...
Liminatus Pharma Inc trading resumes
13:40 EDT Liminatus Pharma (LIMN) Inc trading resumes
Liminatus Pharma Inc trading halted, volatility trading pause
13:30 EDT Liminatus Pharma (LIMN) Inc trading halted, volatility trading pause
Liminatus Pharma initiates strategic review of blockchain-integrated strategy
Liminatus Pharma (LIMN) has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework. This internal r...
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies...
Liminatus Pharma Inc trading halted, volatility trading pause
10:06 EDT Liminatus Pharma (LIMN) Inc trading halted, volatility trading pause
Liminatus Pharma Inc trading resumes
10:11 EDT Liminatus Pharma (LIMN) Inc trading resumes
Liminatus Pharma Inc trading resumes
13:59 EDT Liminatus Pharma (LIMN) Inc trading resumes
Liminatus Pharma Inc trading halted, volatility trading pause
13:54 EDT Liminatus Pharma (LIMN) Inc trading halted, volatility trading pause
Liminatus Pharma files to sell 21.15M shares of common stock for holders
16:51 EDT Liminatus Pharma (LIMN) files to sell 21.15M shares of common stock for holders
Liminatus Pharma files to sell 6.9M shares of common stock
Issuable upon the exercise of the public warrants at an exercise price per share of $11.50.
Liminatus Pharma Inc trading resumes
10:47 EDT Liminatus Pharma (LIMN) Inc trading resumes